| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| ALXN has a current Overall Rating of B (Positive). | 7 |
$25 |
| 28-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Biotechnology Intelligence Monitor: overall outlook STRONG - 25 new Leaders; 18 new Laggards. | 58 |
$20 |
| 28-Nov-2009 | Standard & Poor's STARS Report |
N/A
| Alexion Pharmaceuticals | 8 |
$35 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | ALEXION PHARMACEUTICAL INC (ALXN=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | ALEXION PHARMACEUTICAL INC (ALXN=US) 12-months forecast | 1 |
$15 |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for BIOTECHNOLOGY | 18 |
$49 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: ALEXION PHARM -- ALXN | 1 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ALXN , ANSV , DCGN , HGSI , IDRA -- DRUGS | 3 |
$4 |
| 26-Nov-2009 | New Constructs, LLC |
N/A
| ALXN: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 26-Nov-2009 | Pechala's Reports | Lubomir Pechala | ALEXION PHARMACEUTICALS INC (ALXN=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
1.48% Nasdaq 
Research Reports
